MedPath

A prospective randomized comparative cohort study to investigate abbreviated MRI using Gadoxetic acid and ultrasonography for surveillance of early stage HCC in patients at high risk for HCC

Not Applicable
Recruiting
Conditions
Diseases of the digestive system
Registration Number
KCT0007417
Lead Sponsor
Asan Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
806
Inclusion Criteria

1. The evidence of cirrhosis of any etiology within 12 months prior to screening
Definition of cirrhosis by any of following methods;
1) Histologically by liver biopsy
2) Non-histologically by evidence of portal hypertension in the presence of chronic liver disease
Evidence of portal hypertension includes any of followings;
(1) The identification of splenomegaly on Ultrasonography, CT, or MRI examinations with typical features of liver cirrhosis
(2) The identification of esophageal or gastric varices on endoscopic examination
2. Older than 20 years of age
3. Absence of previous or current history of hepatocellular carcinoma within 6 months prior to screening
4. Eastern Cooperative Oncology Group performance status of 0-2
5. Patient is able to comply with scheduled visits, evaluation plans, and other study procedures.
6. Patient is willing to provide written informed consent

Exclusion Criteria

1. Active or suspected cancer other than hepatocellular carcinoma, or a history of malignancy where the risk of recurrence is equal or higher than 20% within 2 years
2. Significant medical comorbidities in which survival is predicted to be less than 3 years
3. Estimated glomerular filtration rate < 30 mL/min/1.73m^2
(1) Estimated glomerular filtration rate by Modification of Diet in Renal Disease equation = 175 × serum creatinine-1.154 × age-0.203 × 1.212 (if black) × 0.742 (if female)
4. Budd-Chiari Syndrome
5. Precautions for MRI (cardiac pacemaker, severe claustrophobia that may interfere with protocol compliance)
6. Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the completing the study.

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Detection Rate of patients with early stage hepatocellular carcinoma
Secondary Outcome Measures
NameTimeMethod
Detection Rate of patients with very early stage hepatocellular carcinoma;False referral rate of patients with early stage hepatocellular carcinoma;False referral rate of patients with very early stage hepatocellular carcinoma
© Copyright 2025. All Rights Reserved by MedPath